Amplia Therapeutics (ASX:ATX) has reported updated data from its ongoing Phase 2a ACCENT clinical trial investigating its FAK inhibitor narmafotinib in combination with standard-of-care chemotherapy in treating advanced pancreatic cancer. …
Amplia Therapeutics reports updated data from pancreatic cancer trial
March 27, 2025 Australian Biotech
Latest Video
New Stories
-
BioNSW launches BioInvest Catalyst events to support life sciences investment in NSW
March 31, 2025 - - Australian Biotech -
Election writs trigger timeline for the release of remaining budgeted decisions
March 31, 2025 - - Latest News -
New government report reveals the emerging impact of generational reform
March 31, 2025 - - Latest News -
Broader PBS listing recognises cardioprotective benefits of SGLT-2 inhibitor therapy
March 31, 2025 - - Latest News -
The Dispatched 'Week in Review' Podcast - 28 March
March 28, 2025 - - Podcast -
Work of the HTA Review implementation group will continue during caretaker
March 28, 2025 - - Latest News -
Health department quietly launches major review of blood products supply
March 27, 2025 - - Latest News